73
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d15209724e365">The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients. </p>

          Related collections

          Author and article information

          Journal
          The Lancet
          The Lancet
          Elsevier BV
          01406736
          March 2017
          March 2017
          : 389
          : 10072
          : 917-929
          Article
          10.1016/S0140-6736(17)30123-X
          28126333
          bb0d9166-6b3b-4ee5-a20b-31828c6a4f56
          © 2017
          History

          Comments

          Comment on this article